Effects of propofol and dexmedetomidine on inflammatory factorsand infections in patients with lung cancer after radical surgery

OBJECTIVE To investigate the effects of propofol and dexmedetomidine on inflammatory factors and infections in patients with lung cancer after radical surgery,so as to provide evidence for clinical treatment.METHODS A total of 80 cases of patients with lung cancer after radical surgery from Jul.2010 to Mar.2015 were collected,and randomly divided into control group and observation group,with 40 cases in each group.Two groups of patients were given conventional anti-infection and related treatment,and were given dexmedetomidine for sedation.The patients of control group were joint treatment with midazolam,and observation group were given propofol.Vital signs were observed at different time points,and the total number of peripheral blood leukocytes,levels of inflammatory factors,the incidence of infection and infection rates,and adverse events were recorded.RESULTS Comparison of vital signs of the two groups of patients after treatment,after administration of 12 h and 24 h,the MAP began to increase,and the HR,SPO2 and RR began to decline,and there were significant differences compared with the two groups of patients before treatment（P＜0.05）.MAP increased higher in observation group than that in control group,HR,SPO2 and RR reductions were smaller than those in control group,and the differences were significant（P＜0.05）The WBC,TNF-α,and IL-6of observation group were lower than those of control group,IL-10 was higher,and the differences were significant（P＜0.05）.The incidence of pulmonary infection and infection rates of observation group were lower than those of control group,the difference was significant（P＜0.05）,but no significant difference of incision infection rate compared with control group.The symptoms of adverse reactions of the two groups of patients were mild,which did not affect the treatment.CONCLUSION Propofol combined with dexmedetomidine has significant effect on postoperative analgesia for patients with lung cancer,does not affect the patient′s vital signs,inhibit inflammatory cytokine releasing and reduce the incidence of postoperative infections.It is safe,with low adverse reactions incidence,and more worthy of promotion.